Global pharmaceutical group navigating cost cuts and strategic realignment
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight‑loss and diabetes drugs, arguing Lilly used outdated trial data to claim superiority. Lilly defends its campaigns, citing SURMOUNT‑5 results. The case centers on GLP-1 treatments and the race for market dominance, with potential damages and corrective advertising at stake.
GSK has announced a 1.9 billion cost-cutting programme and a shift of more than 1,000 scientists to a new Cambridge R&D campus from Stevenage by 2029, part of broader plans to cut costs and expand late-stage trials.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
Moderna’s mFlusiva (mRNA-1010) has earned FDA approval for adults 50 and older, with full approval for ages 50-64 and accelerated approval for 65+. The decision follows a lengthy review and contrasts with prior FDA scrutiny and political debates surrounding vaccine policy.